Three Yielders Worth a Look Before the Bell Tomorrow

A $278B tobacco name got smacked 3% in a single session, with the ex-div hitting tomorrow morning. A sleepy household-products name bumped its payout.

Again. And a staffing play yielding 2.8% is parked right where the hiring cycle starts to flip.

Tax Strategy (Sponsored)

Looking to Potentially Lower Your 2026 Capital Gains Tax?

Many investors overlook deductions that could help minimize capital gains tax, such as:

• Eligible investment expenses

• Cost basis adjustments

• Selling costs tied to property

Each comes with IRS rules and reporting requirements.

That’s why consulting a fiduciary financial advisor is often recommended.

See Advisor Matches.

Pharma

Pfizer Just Hit a Setback in Its $43 Billion Cancer Push

Pfizer's (NYSE: PFE) experimental lung cancer drug failed to improve survival in patients with advanced disease, creating a setback for one of the cancer assets it gained through its $43 billion Seagen acquisition.

The drug was being watched as part of Pfizer's push to build a stronger oncology business after years of pressure on its broader growth story.

The failure matters because Seagen was not a small side deal. Pfizer bought it to deepen its cancer pipeline, expand into antibody-drug conjugates, and gain additional high-value medicines to support future growth.

Cancer Growth Needs New Winners

Pfizer has been trying to sharpen its future around oncology as older products mature and some pandemic-era revenue fades.

A failed late-stage result in lung cancer slows that effort and puts more attention on the next wave of trials.

The setback also changes your view of execution risk. Pfizer has the scale and research base, but big acquisitions only work when enough pipeline bets turn into approved medicines.

Pipeline Confidence Takes a Hit

The result does not erase Pfizer's cancer strategy, but it makes the path harder.

Lung cancer is a major commercial and medical market, and the lack of survival improvement limits one of the company's more visible opportunities.

Pfizer now needs clean wins elsewhere in oncology to keep the Seagen deal from being judged by its disappointments.

If the company can regain momentum, you have a pharma giant still capable of rebuilding growth but under greater pressure to prove the acquisition can deliver.

PFE currently trades at $24 and pays a dividend of $1.72 per share, a yield of 7.10%.

Energy

Chevron Is Turning AI’s Electricity Problem Into an Energy Business Opening

Pfizer's (NYSE: PFE) experimental lung cancer drug failed to improve survival in patients with advanced disease, creating a setback for one of the cancer assets it gained through its $43 billion Seagen acquisition.

The drug was being watched as part of Pfizer's push to build a stronger oncology business after years of pressure on its broader growth story.

The failure matters because Seagen was not a small side deal.

Pfizer bought it to deepen its cancer pipeline, expand into antibody-drug conjugates, and gain additional high-value medicines to support future growth.

Cancer Growth Needs New Winners

Pfizer has been trying to sharpen its future around oncology as older products mature and some pandemic-era revenue fades.

A failed late-stage result in lung cancer slows that effort and puts more attention on the next wave of trials.

The setback also changes your view of execution risk. Pfizer has the scale and research base, but big acquisitions only work when enough pipeline bets turn into approved medicines.

Pipeline Confidence Takes a Hit

The result does not erase Pfizer's cancer strategy, but it makes the path harder.

Lung cancer is a major commercial and medical market, and the lack of survival improvement limits one of the company's more visible opportunities.

Pfizer now needs clean wins elsewhere in oncology to keep the Seagen deal from being judged by its disappointments.

If the company can regain momentum, you have a pharma giant still capable of rebuilding growth but under greater pressure to prove the acquisition can deliver.

PFE currently trades at $24 and pays a dividend of $1.72 per share, a yield of 7.10%.

Market Catalyst (Sponsored)

Silver Could Be 2026’s Breakout Metal

Silver demand is surging across industries that power the modern economy—EVs, solar, electronics, and defense.

At the same time, supply is falling short, creating what experts call a structural shortage.

Now that the U.S. has classified silver as a “Critical Mineral,” its importance is clearer than ever.

With prices already climbing in 2025, many believe the next leg higher could still be ahead.

Anchor Point Research’s FREE guide shows why silver could outperform—and how to get started.

Access the free report

Enterprise

A Costly Restructuring Shows How Hard Oracle Is Moving Into AI

Oracle (NYSE: ORCL) has cut about 21,000 jobs worldwide, shrinking its workforce from roughly 162,000 employees to about 141,000.

The company linked the reduction to the use of AI in its business processes, while restructuring costs jumped to $1.8 billion.

The move gives Oracle a sharper and more urgent company story.

The business is cutting headcount while pouring more capital into cloud and AI infrastructure, where customers need huge computing capacity for training, inference, and enterprise AI workloads.

Cloud Spending Takes Priority

Oracle has been trying to raise major funding to expand data center capacity as demand from large AI customers continues to climb.

That gives the restructuring a clear business purpose, freeing resources for a cloud buildout that needs capital, energy, chips, and real estate.

The number that should hold your attention is not only the 21,000 jobs. It is the $1.8 billion restructuring bill, because Oracle is paying heavily now to reshape the business around the market it wants to dominate next.

The Risk Is Execution

A smaller workforce can make Oracle more efficient, but it can also create pressure if the company cuts too deeply in important roles.

Oracle itself has warned that restructuring may leave shortages of qualified personnel in some areas.

The urgency comes from timing. AI demand is exploding, cloud rivals are spending aggressively, and Oracle is trying to become a bigger AI infrastructure provider while rebuilding its cost base.

ORCL currently trades at $172 and pays a dividend of $2.00 per share, a yield of 1.16%.

Colgate-Palmolive (CL) raised its quarterly dividend, pushing the new trailing yield to 2.29%.

Fastenal (FAST) hiked its quarterly payout, keeping the annual streak alive.

BXP, Inc. (BXP) bumped its quarterly dividend, with the new yield landing near.

Bank of Montreal (BMO) lifted its quarterly dividend, extending one of the longest streaks among Canadian banks.

Nothing notable in this week's 8-K filings.

Hidden Tax Breaks (Sponsored)

3 Overlooked Deductions to Help Potentially Minimize Capital Gains Tax

Capital gains taxes may quietly reduce more of your investment returns than you realize.

But the tax code includes several strategies that may help reduce that bill.

Three often-overlooked areas include investment-related expenses, cost basis adjustments, and real estate selling costs.

When structured correctly, these deductions may help minimize taxable gains.

Because the rules can be complex, many investors work with fiduciary financial advisors to plan tax-efficient strategies.

Use SmartAsset’s free tool to find vetted financial advisors serving your area.

Everything Else

• 🧭 Three small-cap stocks across AI, energy, and emerging tech are showing subtle early characteristics most investors have not noticed yet.

• 🇪🇺 KNDS is weighing an IPO in Paris or Frankfurt as Europe’s rearmament push keeps lifting defense demand.

• 🤖 Morgan Stanley sees China’s humanoid robot market scaling fast as automation becomes a bigger part of the AI trade.

• 🛡️ Anthropic’s Mythos model reportedly found vulnerabilities in classified U.S. government systems, raising the stakes around AI security.

• 🕶️ Meta rolled out a new range of smart glasses starting at $299, giving its hardware push another consumer test.